Has Michael Frost received payments from drug or device companies?

Yes. Drug and device makers reported $270,571 in general payments to Michael Frost across 327 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Frost did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Frost come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Frost

Internal Medicine · Ambler, PANPI 1962502492

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $202,353 of the $270,571 with a category attached, or 74.8%. Braeburn Inc. accounts for 83.9% of it on its own, with 8 other manufacturers making up the rest. Among internal medicine clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$270,571in general payments, 2019–2025

Across 327 payments — averaging $827.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Braeburn Inc.$227K
Indivior Canada Ltd$12K
Titan Pharmaceuticals, Inc.$11K
Sandoz$10K
Indivior Inc.$8K
USWM, LLC$1K
plus $93 from 3 others

What the payments were for

Consulting fees$27,40410%
Speaking & faculty fees$202,35375%
Travel & lodging$31,16412%
Food & beverage$9,6514%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Braeburn Inc.	253	$226,902
Indivior Canada Ltd	5	$12,275
Titan Pharmaceuticals, Inc.	6	$11,430
Sandoz	6	$10,303
Indivior Inc.	26	$8,240
USWM, LLC	26	$1,328
Biodelivery Sciences International, Inc.	2	$35
AbbVie	2	$35
Verona Pharma, Inc.	1	$23

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

BRIXADI$223,709
SUBLOCADE$19,856
RESET-O$10,255
Probuphine$7,570
RESET$6,081

How this compares

$270,571 in reported general payments places this provider in the 95th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
ZubsolvBuprenorphine Hcl/Naloxone Hcl	26	$25,370
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl	112	$24,576
Doxepin Hcl	24	$1,073
Gabapentin	32	$322
Baclofen	22	$121
Citalopram HbrCitalopram Hydrobromide	21	$27
Venlafaxine Hcl ErVenlafaxine Hcl	11	$18

Paid to pharmacies, not to this prescriber.

Other internal medicine in Ambler

Jonathan EpsteinPhiladelphia$13.1M
Pitamber DevgonPhiladelphia$7.5M
Daniel RaderPhiladelphia$1.7M
Mohammed KidwaiBala Cynwyd$894K
Ronak BhimaniNorristown$623K
David GoldmannPhiladelphia$525K
Christopher StillDanville$442K
Jeffrey FreidLower Gwynedd$425K
Cheryl PegusSpring House$370K
Eyob FeyssaPhiladelphia$328K

See the full list for Pennsylvania →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →